Cardiothoracic & vascular anesthesia

Procalcitonin and interleukin-6 to diagnose infection in cardiac surgery patients with hyperinflammation: a two-centre, prospective cross-sectional study

BJA OpenPublished Diagnostic accuracy study

Authors' conclusion

PCT did not meet clinically important thresholds, offering no valuable diagnostic information in patients with suspected infection early after cardiac surgery, whereas IL-6 did.

Study context

Population
Elective cardiac surgery patients suspected of early-onset infection (abnormal body temperature, blood cultures drawn, or antibiotics within first 3 postoperative days)21 (7%) infection confirmed
Participants
284 patients
Comparison
Procalcitonin (PCT) vs IL-6 for diagnosing infection
Outcome
Diagnostic performance of PCT for infection (-LR <0.2 to rule out, +LR >5 to rule in deemed clinically relevant)
Follow-up
At the time infection was suspected
Methodological detailsprospective, cross-sectional, two-centre
  • Prospective
  • Cross-sectional
  • Two-centre

Performance

As reported in the abstract

Diagnostic performance for infection
Test or modelAUCMinimum -LRMaximum +LR
PCT0.59 (95% CI 0.47-0.71)0.25 at 0.15 μg L-12.07 at 7.16 μg L-1

PCT

AUC0.59 (95% CI 0.47-0.71)
Minimum -LR0.25 at 0.15 μg L-1
Maximum +LR2.07 at 7.16 μg L-1

Further findings

OutcomeValues
IL-6 diagnostic performance for infectionIL-6 AUC 0.70 (95% CI 0.59-0.80) · -LR 0.15 at 73 pg ml-1 · +LR 5.37 at 531 pg ml-1 · ruled out 82 (29%) · ruled in three (1%)

C-reactive protein (CRP), leucocytes and neutrophil/lymphocyte ratio (NLR)

CRP, leukocytes, and NLR did not differentiate between infected and non-infected patients

Original publication

Procalcitonin and interleukin-6 to diagnose infection in cardiac surgery patients with hyperinflammation: a two-centre, prospective cross-sectional study. BJA Open. Published 19 February 2026. doi:10.1016/j.bjao.2026.100538

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.